D.F. McDermott, B.I. Rini, R.J. Motzer, N.M. Tannir, B. Escudier, C.K. Kollmannsberger, H.J. Hammers, C. Porta, S. George, F. Donskov, H.P. Gurney, M-O. Grimm, M. Harrison, T.E. Hutson, J. Doan, S. Yang, S. Rao, S. Mekan, A. Ambavane, T. Powles Department of Medicine, Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center, Boston, MA, USA, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Medical Oncology, Gustave Roussy, Villejuif, France, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada, Division of Hematology and Oncology, UT Southwestern – Kidney Cancer Program, Dallas, TX, USA, Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA, Department of Oncology, Aarhus University Hospital, Aarhus, Denmark, Department of Medical Oncology, Westmead Hospital and Macquarie University, Westmead, Australia, Department of Urology, Jena University Hospital, Jena, Germany, Department of Medicine, Duke University Medical Center, Durham, NC, USA, Department of Medicine, Texas A&M HSC College of Medicine, Dallas, TX, USA, Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA, Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA, Modeling and Simulation, Evidera Inc, London, UK, Department of Medicine, Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK